Department of Justice Awarded a Contract to GLAXOSMITHKLINE, LLC for $2,326.50

Summary of Award

The awarded contract in question involves a transaction made between the Department of Veterans Affairs and GlaxoSmithKline, LLC, a major player in the pharmaceutical preparation manufacturing sector. The contract is identified as a delivery order with the specific purpose of acquiring staff and inmate flu vaccines for the fiscal year 2025. The total obligation for this contract is $2,326.30, a sum that denotes the amount promised by the government to GlaxoSmithKline upon successful fulfillment of the agreement.

**Contract Overview and Details**

The contract has been designated a "C" type, which signifies it as a delivery order. This classification implies that the agency has requested specific goods or services to be delivered within a certain period. The contract’s description highlights its aim to provide flu vaccines for staff and inmates, aligning with public health security measures. The focus on flu vaccines underscores the government's proactive approach to health care for federal employees and the inmate population within the Federal Prison System. The contract, uniquely identified by the number 15B10725F00000037, was signed on April 10, 2025. Its period of performance extends from the signing date to September 15, 2025. This contract aligns with the broad strategy to ensure timely vaccination ahead of the flu season. **Awarding and Funding Agencies** The contract is both funded and awarded by the Department of Justice. Specifically, the Federal Prison System, also known as the Bureau of Prisons, is the sub-agency handling these responsibilities. The contractual activities are managed through the office at FCI Cumberland. The Department of Justice's involvement indicates a focus on institutional health and safety, positioning the vaccine procurement as a priority. **Contract Strategy and Competition** According to the latest transaction contract data, the solicitation procedures followed a "Negotiated Proposal/Quote" route. The extent of competition for this contract was described as "Full and Open," suggesting that multiple vendors could have competed to offer the proposed services or products. However, specific details on the number of offers received were not included in the summary. The contract is characterized by a firm fixed price structure, which suggests that GlaxoSmithKline will be paid the agreed-upon amount without regard to incurred costs. This approach mitigates financial risk for the government as it caps the expense but also allocates responsibility to GlaxoSmithKline to manage its costs effectively. **Recipient Profile: GlaxoSmithKline, LLC** GlaxoSmithKline, LLC (GSK), the recipient of the contract, is a renowned entity within the pharmaceutical industry, specializing in the manufacturing of pharmaceutical preparations. The company is incorporated in the U.S. but classified as foreign-owned, reflecting its global reach. GSK has its operational base in Durham, North Carolina, a significant hub for biotechnology and pharmaceuticals. The location provides strategic advantages, including access to research talent and synergies within the healthcare sector. The business is not designated as a small business, signaling its substantial operations and market footprint. The business categories list GSK as a foreign-owned corporation that is incorporated in the U.S., underlining its international connections and business structure. As a pharmaceutical manufacturer, GSK produces a range of healthcare products, with a significant part of its operations dedicated to developing vaccines, thereby aligning well with the contract's requirements. **Place of Performance** The designated place of performance for this contract is Summit, New Jersey. This location is likely strategic, considering the logistics and distribution networks necessary for the effective delivery of pharmaceutical products to federal institutions such as prisons. Summit's proximity to key transportation hubs facilitates timely distribution, particularly during the crucial pre-flu season period. **Transaction Details** Regarding the specific transactions tied to this contract, there is initial evidence of a singular transaction dated April 10, 2025, coinciding with the contract's signing. The transaction aligned with the total award amount of $2,326.30. No modifications or additional subsidy costs were detailed beyond this initial financial commitment, suggesting a straightforward transaction process. The unique internal identification, CONT_AWD_15B10725F00000037_1540_36E79724D0005_3600, aids in tracking and future reference. No loan value or def codes were associated, implying a straightforward purchase without leveraged funds or deferred reinforcement codes. **Conclusion** The summerization of this federal contract highlights a focused attempt by the government to enhance health measures within the Federal Prison System through comprehensive vaccination efforts. By partnering with GlaxoSmithKline, a prominent pharmaceutical entity, the Department of Justice ensures a reliable supply of flu vaccines to mitigate potential health risks within its institutions. The delivery order underpins a strategy of proactive health management, underscoring the government's commitment to safeguarding public health, particularly in congregate settings like federal prisons.